Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
10 July 2018
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer.
Keywords: low dose naltrexone, Chron's disease, non-small cell lung cancer, neurodegenerative conditions, autoimmune disorders, human immunodeficiency virus, endorphins, proclaim trial, metkephalin